[ET Net News Agency, 31 December 2020] Huatai Research initiated coverage on Sino
Biopharmaceutical (SNB) (01177) with a "buy" rating and a target price of HK$10.58.
The research house said SNB is one of the largest-scale pharmaceutical companies,
equipped with leading commercial and R&D teams, in China. Huatai favors SNB's evolution
into a novel drug-driven company, considering the solid sales growth of anlotinib and a
robust pipeline led by PD-1/PD-L1 mAbs and small molecular drugs.
It forecast SNB's revenue at RMB23.8bn/RMB27.2bn/RMB32.1bn in 2020/21/22 with a two-year
CAGR of 16.1% and net profit at RMB2.7bn/RMB3.2bn/RMB3.8bn with a two-year CAGR of 18.7%.
(KL)